Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study

Heng Liu MD1,*  |  Liang Zhou MM2,*  |  Hugen Wang MM1,*  |  Xiaobo Wang MM2  |  Guangbo Qu PhD4  |  Jing Cai MM3  |  Hong Zhang MD2

1Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Hefei, PR, China
2Emergency Department, First Affiliated Hospital of Anhui Medical University, Hefei, PR, China
3Department of Rheumatology, First Affiliated Hospital of Anhui Medical University, Hefei, PR, China
4Department of Epidemiology and Health, School of Public Health, Anhui Medical University, Hefei, PR, China

Correspondence
Hong Zhang, MD, Emergency Department, First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, P.R. China.
Email: zhanghong20070703@163.com

*Heng Liu, Liang Zhou, and Hugen Wang contributed equally to this work.

Background: Coronavirus disease 2019 (COVID-19) is spreading globally and has caused many deaths. This study investigated, for the first time, COVID-19 patients’ nutrition status and its effects on their inflammatory and immune responses.

Methods: Forty-seven COVID-19 patients were recruited for this prospective study. According to the subjective global assessment at admission, patients were divided into the normal nutrition (NN), risk of malnutrition (RMN), or MN group. Serum cytokines and whole blood T-cell subpopulations were measured to assess the inflammatory and immune responses in COVID-19 patients. Analysis of covariance and χ² tests were used.

Results: On admission, the incidences of MN and the RMN in COVID-19 patients were 17.0% and 38.3%, respectively. The MN group had a higher proportion with severe/critical COVID-19 and a longer hospitalization duration than the NN group. Serum interleukin (IL) 6 concentrations were elevated in 97.9% of the patients and were the highest in malnourished patients. The IL-4 and IL-10 levels were elevated in 46.8% and 48.9% of the patients, respectively. The proportion of CD8+ T cells was significantly lower in the MN group than in the NN group.

Conclusion: A high proportion of COVID-19 patients are malnourished or at risk of malnourishment, especially those with severe disease. MN is associated with hyperinflammation and immunosuppression in COVID-19 patients, and it may contribute to disease progression.

Keywords
coronavirus disease 2019, cytokines, immunosuppression, inflammation, malnutrition, nutrition status
INTRODUCTION

In December 2019, a cluster of cases of pneumonia of unknown etiology were identified in Wuhan, Hubei Province, China. A novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from a pneumonia patient and suspected of being the causative pathogen. The disease caused by the virus was called coronavirus disease 2019 (COVID-19) by the World Health Organization. The virus spread from Wuhan to all of China and had caused 89,905 cases of COVID-19, including 4710 deaths, as of August 17, 2020. Because of the initiation of effective government interventions, the outbreak of COVID-19 is under control in mainland China. However, there has been a steady increase in the daily total number of COVID-19 cases globally. To date, >21 million cases of COVID-19 have been confirmed in 183 countries/regions, and COVID-19 has become a major global health concern.

Most COVID-19 patients have mild symptoms and a good prognosis. However, some patients rapidly develop acute respiratory distress syndrome (ARDS) and multiple organ failure (MOF), leading to death. Cytokine storms may play a crucial role in the progression of COVID-19 and are also a leading cause of ARDS and MOF. In patients with severe COVID-19, controlling the cytokine storm increases their chance of survival.

Nutrition status is an important factor that influences the host defense against pathogenic organisms. Epidemiological and clinical data suggest that malnutrition (MN) plays a role in acute and chronic infections, possibly because of an underlying immunodeficiency, which substantially increases the incidence of disease as well as its severity. Disease progression can in turn exacerbate malnutrition, leading to a vicious cycle. COVID-19 is a new, acute infectious disease, and the nutrition status of COVID-19 patients has not yet been examined. Additionally, the associations of nutrition status with the inflammatory and immune responses in COVID-19 patients needs to be elucidated.

We performed a prospective observational study to assess the nutrition status in COVID-19 patients and investigate its association with their immune responses.

MATERIALS AND METHODS

Patients

This prospective observational study was approved by The First Affiliated Hospital of Anhui Medical University Committee on Medical Ethics in compliance with the Chinese national regulations and standards for ethical research (Quick-J-2020-04-11). Patients enrolled in this study signed informed consent forms. All procedures were performed in accordance with the principles of the Declaration of Helsinki. We prospectively collected the records of inpatients with laboratory-confirmed COVID-19 from Cancer Center of Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China. The inclusion criteria were age ≥15 years and two positive results on real-time polymerase chain reaction assays (TaqMan One-Step real-time PCR Kits from Shanghai Huirui Biotechnology Co, Ltd or Shanghai BioGerm Medical Biotechnology Co, Ltd) for SARS-CoV-2 from nasopharyngeal swab specimens. The exclusion criteria were age <15 years, pregnancy, and inability to reliably assess the patient's nutrition (eg, comatose or confused patients).

Nutrition status assessment

This study evaluated nutrition status by using the subjective global assessment (SGA) at admission. The SGA was administered as described by Detsky and colleagues. The SGA is a valid and reliable tool that assesses nutrition status on the basis of the features available in the medical history (weight change, dietary intake change, gastrointestinal symptoms that have persisted for >2 weeks, changes in functional capacity) and on physical examination (loss of subcutaneous fat, muscle wasting, ankle/sacral edema, and ascites). These features were combined subjectively into an overall or global assessment, and patients were rated as well nourished, suspected of being malnourished, or severely malnourished. The SGA was administered for COVID-19 patients by a single dietitian who was very experienced with this assessment. According to the SGA, the patients were divided into three groups: the normal nutrition (NN) group, risk of malnutrition (RMN) group, and MN group.

Clinical treatment

According to the guidelines for COVID-19 (trial fifth edition) issued by the China National Health Commission, patients were divided into four groups: mild, moderate, severe, and critical disease. Mild disease was characterized by mild clinical symptoms and no signs of pneumonia on imaging. Moderate disease was characterized by fever, respiratory tract symptoms, and signs of pneumonia on imaging. Patients were diagnosed with severe COVID-19 if they met any of the following criteria: (1) shortness of breath, with a respiratory rate (RR) >30 times/min; (2) a mean oxygen saturation ≤93% at rest; or (3) a partial
pressure of arterial oxygen/oxygen concentration ≤ 30 mm Hg (1 mm Hg = 0.133 kPa), with evidence on pulmonary imaging that the lesions had progressed significantly within 24 to 48 h or involvement of >50% of the lung. Critical disease was defined as the presence of any of the following conditions: (1) respiratory failure necessitating mechanical ventilation, (2) shock, or (3) any organ failure necessitating monitoring and treatment in the intensive care unit (ICU).13

Routine therapies, such as bed rest, enhanced nutrition support, oxygen therapy, antiviral therapy, and monitoring, were used for patients with mild and moderate COVID-19. However, patients with severe and critical COVID-19 received more life-support therapies, such as mechanical ventilation, continuous renal replacement therapy, and extracorporeal membrane oxygenation.

Clinical data collection

Epidemiological, demographic, clinical, and outcome data were collected from the patients' medical records. Other nutrition parameters, such as the body mass index (BMI), white blood cell (WBC) count, hemoglobin (Hb) level, lymphocyte count (LYM), creatinine (Cr) level, hypersensitive C-reactive protein (hsCRP) level, serum albumin (ALB) level, and transferrin (TF) level, were also collected. Clinical outcomes were followed up to April 15, 2020. A nurse on our research team collected all the relevant data, which were independently rechecked by two other researchers.

Cytokine and T-cell subpopulation measurements

To assess changes in inflammatory and immune responses in COVID-19 patients, we examined a range of cytokines and T-cell subpopulations. Serum proinflammatory cytokines (interleukin [IL] 2, IL-6, tumor necrosis factor-α, and interferon-γ [IFN-γ]) and antiinflammatory cytokines (IL-4 and IL-10) were measured in all patients by using a Human Cytokine Standard 27-Plex Assay panel (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. The phenotypic analysis of lymphocytes (CD3+, CD4+, and CD8+ T cells) in the peripheral blood was performed with a FACSCalibur CellSorting System (BD Bioscience, San Jose, CA, USA).

Statistical analysis

Continuous variables are presented as the means and SEs, and the significance of differences among groups was assessed with analysis of covariance, in which disease severity was used as a covariate. Categorical variables are presented as numbers (percents) and were compared with the χ² test or Fisher exact test. A two-sided P < .05 was considered statistically significant. All statistical analyses were performed with SPSS software (version 21.0, IBM).

RESULTS

Demographics and baseline characteristics

Eighty-two COVID-19 patients were screened, but 35 of them were excluded on the basis of the criteria. Finally, a total of 47 COVID-19 patients were recruited from February 14, 2020, to March 14, 2020. All patients were discharged from the hospital at the end of follow-up. The flowchart outlining patient selection is presented in Figure 1.

All of the recruited patients had lived in Wuhan for a long time, and none of them had a history of exposure to the local Huanan South China Seafood Market in Wuhan city. In total, 8 (17.0%) patients were part of familial clusters of cases. COVID-19 patients enrolled in the study (n = 47) were distributed unevenly among the nutrition categories (NN, n = 21; RMN, n = 18; and MN, n = 8), and the majority were males (51.1%). Patient ages ranged from 29 to 92 years, with a median of 68 years. The duration of disease (time from symptom onset to admission) ranged from 5 to 30 days, with a median of 15 days. Twenty-one (44.7%) of the COVID-19 patients were aged 66–75 years, and 8 (17.0%) were aged >75 years (Table 1). Of the 47 patients, 29 (61.7%) had chronic diseases, including cardiovascular disease (46.8%, 22 of 47), endocrine system disease (23.4%, 11 of 47), digestive system disease (17.0%, 8 of 47), respiratory system disease (4.3%, 2 of 47), and malignancy (8.5%, 4 of 47). Fever (76.6%, 36 of 47), dry cough (42.6%, 20 of 47), and respiratory distress (51.1%, 24 of 47) were the most common symptoms at the onset of illness (Table 1).

On admission, the incidences of MN and the RMN in COVID-19 patients were 17.0% (8 of 47, MN group) and 38.3% (18 of 47 RMN group), respectively. A total of 44.7% (21 of 47) of the patients had NN status (NN group) (Table 1). There were no significant differences in sex and mean age among the three groups. Additionally, the mean duration of disease was not significantly different among the three groups. Consistent with the nutrition status assessment, the BMI value was the lowest in the MN group (17.7 ± 1.3), followed by the RMN group (23.0 ± 0.7; all P values < .001). A total of 50.0% (4 of 8) of the patients in the MN group had a history of malignant tumors. The prevalence of endocrine system disease in the RMN group (44.4%, 8 of 18) was significantly higher than...
FIGURE 1  Flowchart outlining participant selection. COVID-19, coronavirus disease 2019; SGA, subjective global assessment

Laboratory and clinical findings

The blood counts on admission showed lymphopenia (42.6%, 20 of 47), especially in the MN group ($P = .001$) (Table 2). The levels of both ALB and TF, which are inflammatory markers, were lower in the MN group than in the other two groups on admission (all $P < .05$). The proportion of patients with an increased level of hsCRP was higher in the MN group than in the other two groups. However, the mean level of hsCRP was not significantly different among the three groups. The three groups did not differ significantly in the WBC count or Hb level.

The proportion of patients with severe and critical disease was significantly higher in the MN group than in the NN group and RMN group ($P < .001$) (Table 2). Most of the COVID-19 patients (78.7%, 37 of 47) received antiviral treatment, and there were no differences among the three groups. Antibiotic treatment was more often administered in the NN group than in the other two groups (75.0%, 6 of 8; $P = .045$). Traditional Chinese medicine plays an important role in the treatment of COVID-19. The majority of patients received this treatment in the study, and no differences were found among the three groups. No patients died during hospitalization, and all patients were discharged at the end of follow-up. The mean length of stay in the MN group was significantly longer than that in the NN group (21.8 ± 7.3 days; $P = .028$).

Cytokines and T-cell subpopulation

The serum concentration of IL-6 in the MN group (30.7 ± 7.1 pg/ml) was higher than those in the other two groups ($P = .016$). The serum levels of TNF-α, IFN-γ, IL-4 and IL-10 were not significantly different among the three groups.

The distribution of the T-cell subpopulations differed among the three groups. In particular, the proportion of CD8+ T cells was significantly lower in the MN group than in the NN group ($P = .027$) (Table 3). The proportions of CD3+ and CD4+ T cells were similar among the three
|          | Total (N = 47) | NN group (n = 21) | RMN group (n = 18) | MN group (n = 8) | P-value |
|----------|---------------|-------------------|--------------------|-----------------|---------|
| Gender   |               |                   |                    |                 |         |
| Male     | 23 (48.9)     | 13 (61.9)         | 7 (38.9)           | 3 (37.5)        | .319    |
| Female   | 24 (51.1)     | 8 (38.1)          | 11 (61.1)          | 5 (62.5)        |         |
| Mean age, years | 63.4 ± 2.9 | 65.4 ± 3.1        | 67.6 ± 5.9         |                 | .785    |
| Mean duration of disease, days | 19.1 ± 1.9 | 18.6 ± 2.0        | 19.9 ± 3.9         |                 | .634    |
| BMI      | 25.5 ± .6a    | 23.0 ± .7b        | 17.7 ± 1.3c        |                 | <.001   |
| Comorbidity |           |                   |                    |                 |         |
| Cardiovascular diseases | 22 (46.8) | 9 (42.9)          | 7 (38.9)           | 6 (75.0)        | .250    |
| Endocrine system disease | 11 (23.4) | 3 (14.3)          | 8 (44.4)           | 0               | .025    |
| Digestive system disease | 8 (17.0) | 6 (28.6)          | 1 (5.6)            | 1 (12.5)        | .139    |
| Respiratory system disease | 2 (4.3) | 1 (4.8)           | 1 (5.6)            | 0               | 1.000   |
| Malignant tumor | 4 (8.5) | 0                 | 0                  | 4 (50.0)        | <.001   |
| Signs and symptoms |          |                   |                    |                 |         |
| Fever    | 36 (76.6)     | 19 (90.5)         | 11 (61.1)          | 6 (75.0)        | .077    |
| Dry cough| 20 (42.6)     | 9 (42.9)          | 8 (44.4)           | 3 (37.5)        | 1.000   |
| Expectoration | 13 (27.7) | 4 (19.0)          | 6 (33.3)           | 3 (37.5)        | .512    |
| Chest distress | 24 (51.1) | 13 (61.9)         | 7 (38.9)           | 4 (50.0)        | .399    |
| Fatigue  | 14 (29.8)     | 9 (42.9)          | 5 (27.7)           | 0               | .091    |
| Diarrhea | 9 (19.2)      | 7 (33.3)          | 1 (5.6)            | 1 (12.5)        | .080    |
| Headache | 4 (8.5)       | 2 (9.5)           | 2 (11.1)           | 0               | 1.000   |

**Note:** Values are mean ± SE or frequency (percent). **Labeled means in a row that do not share a common letter differ significantly (P < .05).**

**Abbreviations:** BMI, body mass index; MN group, malnutrition group; NN group, normal nutrition group; RMN group, risk of MN group.

The basic epidemiological and clinical features were reported. In this study, 17.0% of the COVID-19 patients were part of a familial cluster of cases, with no significant difference between the sexes. Because of the high proportion of elderly patients, with 61.7% of patients older than 66 years, most of the patients had underlying diseases. Different durations of disease can influence the inflammatory and immune responses in COVID-19 patients. There were no significant differences in disease duration among the three groups, which suggested that the inflammatory and immune responses should be comparable. Consistent with previous studies, fever and respiratory symptoms were the most common clinical manifestations in COVID-19 patients. Patients had differing levels of severity of gastrointestinal symptoms, such as diarrhea and a poor appetite, which could have led to changes in their nutrition status.

By administering a nutrition status assessment, we found that 51.1% of the COVID-19 patients were at RMN or were already undernourished at admission; this was especially true for elderly patients. The BMI value was related to the results of the SGA, confirming the accuracy of the nutrition assessment.

Laboratory tests showed that the LYM count was significantly lower in patients in the MN group than in patients in the NN group. Huang et al found that 85% of patients with COVID-19 treated in the ICU had lymphocytopenia.

**DISCUSSION**

As an emerging infectious disease, COVID-19 is currently spreading around the world and has caused hundreds of thousands of deaths. The prevention, diagnosis, and treatment of COVID-19 are currently being studied by doctors and scientists around the world. It is well known that nutrition plays an important role in the occurrence and development of and recovery from diseases. However, to date, there have been no reports on the nutrition status of COVID-19 patients. This study was conducted to clarify the nutrition status of COVID-19 patients and its effects on their inflammatory and immune responses. This study had two important findings. First, 17.0% of the COVID-19 patients were malnourished, which was associated with more severe disease and a prolonged duration of hospitalization. Second, MN promotes hyperinflammation and immunosuppression in COVID-19 patients.
**TABLE 2**  Nutrition status and clinical characteristics of coronavirus disease 2019 patients at admission

| Laboratory results                        | Total (N = 47) | NN group (n = 21) | RMN group (n = 18) | MN group (n = 8) | P-value |
|------------------------------------------|----------------|------------------|--------------------|------------------|---------|
| WBC (whole blood), x10⁹/L               |                |                  |                    |                  |         |
| <3.50                                    | 3 (6.4)        | 0                | 3 (16.7)           | 0                | .197    |
| 3.50–10.00                               | 41 (87.2)      | 21 (100.0)       | 13 (72.2)          | 7 (87.5)         | .533    |
| >10.00                                   | 3 (6.4)        | 0                | 2 (11.1)           | 1 (12.5)         |         |
| Hb (whole blood), g/L                   | 121.9 ± 2.6    | 115.9 ± 2.8      | 122.2 ± 5.4        | .241             |
| <120.00                                  | 28 (59.6)      | 11 (52.4)        | 12 (66.7)          | 5 (62.5)         | .533    |
| ≥120.00                                  | 19 (40.4)      | 10 (47.6)        | 6 (33.3)           | 3 (37.5)         |         |
| LYM (whole blood), x10⁹/L               | 1.4 ± .1       | 1.3 ± .1         | .7 ± .2            | .259             |
| <1.100                                   | 20 (42.6)      | 5 (23.8)         | 3 (16.7)           | 0                | .197    |
| ≥1.100                                   | 27 (57.4)      | 16 (76.2)        | 11 (61.1)          | 0                |         |
| ALB (serum) level, g/L                  | 36.6 ± 1.0     | 35.0 ± 1.0       | 31.9 ± 2.2         | .019             |
| <35.00                                   | 21 (44.7)      | 6 (28.6)         | 9 (50.0)           | 6 (75.0)         | .066    |
| ≥35.00                                   | 26 (55.3)      | 15 (71.4)        | 9 (50.0)           | 2 (25.0)         |         |
| TF (serum), g/L                         | 7.0 ± 5.0      | 11.4 ± 5.2       | 26.8 ± 10.1        | .259             |
| <2.00                                    | 8 (17.0)       | 1 (4.8)          | 2 (11.1)           | 5 (62.5)         | .001    |
| ≥2.00                                    | 39 (83.0)      | 20 (95.5)        | 16 (88.9)          | 3 (37.5)         |         |
| hsCRP (serum), mg/L                     | 7.0 ± 5.0      | 11.4 ± 5.2       | 26.8 ± 10.1        | .259             |
| <4.00                                    | 26 (55.3)      | 16 (76.2)        | 7 (38.9)           | 3 (37.5)         | .059    |
| >4.00                                    | 21 (44.7)      | 5 (23.8)         | 11 (61.1)          | 5 (62.5)         |         |
| Patient types                            |                |                  |                    |                  | <.001   |
| Mild and moderate types                  | 36 (76.6)      | 19 (90.5)        | 16 (88.9)          | 1 (12.5)         |         |
| Severe and critical types                | 11 (23.4)      | 2 (9.5)          | 2 (11.1)           | 7 (87.5)         |         |
| Treatment                                |                |                  |                    |                  |         |
| Antiviral treatment                      | 37 (78.7)      | 16 (76.2)        | 15 (83.3)          | 6 (75.0)         | .107    |
| Antibiotic treatment                     | 19 (40.4)      | 6 (28.6)         | 7 (38.9)           | 6 (75.0)         | .045    |
| Traditional Chinese medical treatment    | 32 (68.1)      | 15 (71.4)        | 12 (66.7)          | 5 (62.5)         | .208    |
| Length of stay, days                     | 13.5 ± 5.5     | 18.3 ± 4.3       | 21.8 ± 7.3         | .028             |

*Note: Values are mean ± SE or frequency (percent). Labeled means in a row that do not share a common letter differ significantly, P < .05.*

**Abbreviations:** ALB, albumin; Hb, hemoglobin; hsCRP, hypersensitive C-reactive protein; LYM, lymphocyte; MN group, malnutrition group; NN group, normal nutrition group; RMN group, risk of MN group; TF, transferrin; WBC, white blood cell.

**TABLE 3**  Cytokines and T-cell subpopulation in coronavirus disease 2019 patients at admission

| Cytokines            | NN group (n = 21) | RMN group (n = 18) | MN group (n = 8) | P-value |
|----------------------|------------------|--------------------|------------------|---------|
| IL-2 (serum), pg/ml  | 3.3 ± .2         | 3.9 ± .3           | 3.4 ± .5         | .213    |
| IL-6 (serum), pg/ml  | 9.8 ± 3.4       | 12.8 ± 3.7         | 30.7 ± 7.1       | .016    |
| TNF-α (serum), pg/ml | 3.7 ± .3         | 3.3 ± .3           | 3.2 ± .5         | .525    |
| IFN-γ (serum), pg/ml | 2.6 ± .3         | 3.2 ± .3           | 4.0 ± .6         | .121    |
| IL-4 (serum), pg/ml  | 2.7 ± .3         | 3.4 ± .3           | 2.6 ± .6         | .137    |
| IL-10 (serum), pg/ml | 4.3 ± .3         | 4.8 ± .4           | 4.6 ± .7         | .597    |

*T-cell subpopulation (whole blood)*

| CD3⁺, %               | 68.0 ± 2.2       | 70.1 ± 2.4        | 72.6 ± 4.6       | .637    |
| CD4⁺, %               | 42.3 ± 1.7       | 42.9 ± 1.8        | 51.7 ± 3.4       | .230    |
| CD8⁺, %               | 23.2 ± 1.5       | 24.0 ± 1.5        | 15.9 ± 2.9       | .027    |
| CD4/CD8               | 2.0 ± 3.8        | 1.9 ± 3.6         | 4.2 ± 6.8        | .015    |

*Note: Values are mean ± SE. Labeled means in a row that do not share a common letter differ significantly, P < .05.*

**Abbreviation:** CD, cluster of differentiation; IFN-γ, interferon-γ; IL, interleukin; MN group, malnutrition group; NN group, normal nutrition group; RMN group, risk of MN group; TNF-α, tumor necrosis factor-α.
but only 54% of patients not treated in the ICU had lymphocytopenia.\(^8\) A later large-sample study also showed that patients with severe disease had more prominent lymphocytopenia than those with nonsevere disease.\(^7\) These results suggest that lymphocytopenia may be related to the severity of COVID-19. The proportion of patients with severe and critical COVID-19 was significantly higher than the proportion with mild and moderate COVID-19 in the MN group. Regarding treatment, there were no significant differences in the administration of antiviral treatment and traditional Chinese medicine treatment among the groups. However, the proportion of patients who received antibiotic treatment in the MN group was significantly higher than in the other two groups, which may be related to the susceptibility to bacterial coinfections in patients in the MN group. In a retrospective study of 1099 COVID-19 patients, similar results were obtained; up to 80.3% of the patients with severe disease needed antibiotic treatment.\(^7\) In terms of the final clinical outcome, the mean length of stay in the MN group was also significantly longer than that in the NN group. The above results show that MN is not only a consequence of COVID-19 but also may contribute to disease progression. A study in pneumococcal pneumonia patients found that elderly patients had lower levels of serum ALB, which was associated with disease progression and a prolonged length of stay.\(^16\) A randomized control trial also showed that nutrition intervention programs for malnourished elderly adults with pneumonia significantly improved their nutrition status and reduced the readmission rate.\(^17\)

In the host response to infection with SARS-CoV-2, the nonspecific immune response is activated first, and immune cells produce cytokines to destroy the virus. Then, the specific immune response is activated, and the appropriate T cells or B cells are selected.\(^18\) Early studies showed that increased levels of proinflammatory cytokines (eg, IL-1B, IL-6, IL-12 and IFN-\(\gamma\)) were associated with pulmonary inflammation and extensive lung damage in SARS patients.\(^19\) Middle East respiratory syndrome coronavirus (MERS-CoV) infection was also reported to induce increases in the concentrations of proinflammatory cytokines (IFN-\(\gamma\), TNF-\(\alpha\), IL-15, and IL-17).\(^20\) We also observed that the levels of the proinflammatory cytokine IL-6 were increased in COVID-19 patients. Previous studies showed increased levels of IL-6 in 52.0% of COVID-19 patients.\(^21,22\) Moreover, patients treated in the ICU had higher levels of granulocyte colony stimulating factor, IP10, monocyte chemotactic protein 1 (MCP1), active macrophage inflammatory protein 1-\(\alpha\), and TNF-\(\alpha\) than those not treated in the ICU, suggesting that cytokine levels were associated with disease severity.\(^3,18\) We found that the concentration of IL-6 was the highest in the MN group among the three groups, with a mean concentra-


our study also showed lower CD8+ T-cell counts in the MN group than in the other two groups. However, there was no difference in the proportions of CD4+ and CD3+ T cells among the three groups. COVID-19 patients had high levels of cytokines (IL-1β, IFN-γ, IL-6, TNF-α, IP10, and MCP1), probably leading to the activation of T-helper-1 (Th1) (CD4+) cell responses. Current evidence strongly suggests that the Th1-type response is key for the successful control of SARS-CoV and MERS-CoV; it is likely that the same is true for SARS-CoV-2.36 CD8+ T cells play an important role in protecting against infections and reinfections with intracellular pathogens such as viruses.37 Therefore, the reduced count of CD8+ T cells in the MN group of COVID-19 patients may damage the body’s ability to clear SARS-CoV-2, leading to the progression of the disease. Animal experiments showed that MN inhibited the CD8+ T-cell response by altering the bone marrow microenvironment and reducing virus-specific CD8+ T cells.38 MN may play an accessory role in the immune dysfunction in COVID-19 patients. Some immune enhancers, such as thymosin, may be used in patients with severe and critical COVID-19 with immune dysfunction.

Limitations of this study should be mentioned. Although this was a prospective study, the patients were evaluated by the SGA only on admission, and their nutrition status might have changed as the disease developed; therefore, a single evaluation might not adequately reflect their nutrition status. Because of the small sample size of this study, confounding is also a factor to be considered in the analysis, and the results need to be verified by a study with a larger sample size. Furthermore, all patients were from the same center; the homogeneity of the study population and therapeutic environment may have precluded the identification of certain factors affecting the COVID-19 treatment outcome. However, among the studied variables, no other variable was identified that improved the predictive model. A prospective study in multiple centers assessing many time points is needed to confirm and refine our findings.

CONCLUSIONS

Our findings reveal that a high proportion of COVID-19 patients are malnourished or at RMN, especially those with severe disease. MN promotes hyperinflammation and immunosuppression in COVID-19 patients, which ultimately may lead to disease progression. Therefore, a timely and effective assessment of the nutrition status of COVID-19 patients and active nutrition interventions for those at RMN may contribute to improved outcomes.

CONFLICT OF INTEREST

None declared.

FUNDING INFORMATION

None declared.

AUTHOR CONTRIBUTIONS

Heng Liu and Hong Zhang equally contributed to the conception and design of the research; Liang Zhou and Hugen Wang contributed to the design of the research; Guangbo Qu contributed to the acquisition and analysis of the data; Xiaobo Wang and Jing Cai contributed to the interpretation of the data; and Heng Liu drafted the manuscript. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

ORCID

Hong Zhang MD https://orcid.org/0000-0002-6236-2475

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. China novel coronavirus investigating and research team. a novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382(8):727-733.
2. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Version 2. Chinese Med J. 2020;133(9):1015-1024.
3. Coronavirus Study Group of the International Committee on taxonomy of viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Version 2. Nat Microbiol. 2020;5(4):536-544.
4. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. Accessed February 11, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
5. National Health Commission of the People’s Republic of China. 2020. Accessed August 17, 2020. http://www.nhc.gov.cn/
6. World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020. Accessed August 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
9. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
10. Bourke CD, Berkley JA, Prendergast AJ. Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol. 2016;37(6):386-398.
11. Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of childhood malnutrition on host defense and infection. Clin Microbiol Rev. 2017;30(4):919-971.
12. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status?. *JPEN J Parenter Enteral Nutr*. 1987;11(1):8-13.

13. General Office of National Health Committee. Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial fifth edition). 2020. Accessed February 5, 2020. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm

14. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. *Int J Antimicrobial Agents*. 2020;55(3):105924.

15. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. *Emerg Microbes Infect*. 2020;9(1):727-732.

16. Akuzawa N, Naito H. Nutritional parameters affecting severity of pneumonia and length of hospital stay in patients with pneumococcal pneumonia: a retrospective cross-sectional study. *BMC Pulm Med*. 2015;15(1):149.

17. Yang PH, Lin MC, Liu YY, Lee CL, Chang NJ. Effect of nutritional intervention programs on nutritional status and readmission rate in malnourished older adults with pneumonia: a randomized controlled trial. *Int J Environ Res Public Health*. 2019;16(23):4758.

18. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Sem Immunopathol*. 2017;39(5):529-539.

19. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Experiment Immunol*. 2004;136(1):95-103.

20. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Sulieman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine*. 2018;104:8-13.

21. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513.

22. Wan S, Yi Q, Fan S, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. *Brit J Haematol*. 2020;189(3):428-437.

23. Malavé I, Vethencourt MA, Chacón R, Quijones D, Rebrij C, Bolívar G. Production of interleukin-6 in cultures of peripheral blood mononuclear cells from children with primary protein-calorie malnutrition and from eutrophic controls. *Ann Nutr Metabol*. 1998;42(5):266-273.

24. Songür N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. *Tumori*. 2004;90(2):196-200.

25. Honda H, Qureshi AR, Heimbünger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis*. 2006;47(1):139-148.

26. Miroliæe AE, Salamzadeh J, Shokouhi S, Sahraei Z. The study of vitamin D administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator associated pneumonia. *J Crit Care*. 2018;44:300-305.

27. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intens Care Med*. 2020;46(5):846-848.

28. Gupta KK, Khan MA, Singh SK. Constitutive inflammatory cytokine storm: a major threat to human health. *J Interf Cytok Res*. 2020;40(1):19-23.

29. Valent P. KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-4. *Haematolgia*. 2020;105(1):6.

30. Hatada T, Miki C. Nutritional status and postoperative cytokine response in colorectal cancer patients. *Cytokine*. 2020;12(9):1331-1336.

31. Huang KJ, Su JI, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. *J Med Virol*. 2005;75(2):185-194.

32. Fock RA, Vinolo MA, Crisma AR, Nakajima K, Rogero MM, Borelli P. Protein-energy malnutrition modifies the production of interleukin-10 in response to lipopolysaccharide (LPS) in a murine model. *J Nutr Sci Vitaminol*. 2008;54(5):371-377.

33. Santos AC, Correia CA, de Oliveira DC, Nogueira-Pedro A, Borelli P, Fock RA. Intravenous glutamine administration modulates TNF-alpha/IL-10 ratio and attenuates NFkB phosphorylation in a protein malnutrition model. *Inflammation*. 2016;39(6):1883-1891.

34. Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. *Oral Oncol*. 2020;106:104659.

35. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8(4):420-422.

36. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol*. 2020;38(1):1-9.

37. Gerritsen B, Pandit A. The memory of a killer T cell: models of CD8(+) T cell differentiation. *Immunol Cell Biol*. 2016;94(3):236-241.

38. Chattraw JH, Wherry EJ, Ahmed R, Kapasi ZF. Diminished primary CD8 T cell response to viral infection during protein energy malnutrition in mice is due to changes in microenvironment and low numbers of viral-specific CD8 T cell precursors. *J Nutr*. 2008;138(4):806-812.

**How to cite this article:** Liu H, Zhou L, Wang H, et al. Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study. *Nutr. Clin. Pract.* 2021;1–9. https://doi.org/10.1002/ncp.10679